Establishment Labs Announces Participation in the UBS Global Healthcare Virtual Conference

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the UBS Global Healthcare Virtual Conference, taking place from May 24-26, 2021. CEO Juan José Chacón-Quirós and CFO Renee Gaeta will present on May 24, 2021, at 9:00 am ET. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Establishment Labs specializes in women’s health, focusing on breast aesthetics and reconstruction, and markets silicone gel-filled Motiva Implants®, available in over 80 countries.

Positive

• Participation in a major healthcare conference may enhance visibility and investor interest.
• Motiva Implants® are available in over 80 countries, indicating strong market presence.

Negative

• None.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the UBS Global Healthcare Virtual Conference, which is being held May 24-26, 2021. Mr. Chacón-Quirós and Mrs. Gaeta are scheduled to speak to conference attendees at 9:00 am ET on Monday, May 24, 2021.

A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005268/en/

FAQ

When will Establishment Labs participate in the UBS Global Healthcare Virtual Conference?

Establishment Labs will participate in the conference on May 24, 2021, at 9:00 am ET.

What is the focus of Establishment Labs' business?

Establishment Labs focuses on women's health, particularly in the breast aesthetics and reconstruction market.

What is the stock symbol for Establishment Labs?

The stock symbol for Establishment Labs is ESTA.

How can I access the live webcast of the Establishment Labs conference presentation?

The live webcast can be accessed on Establishment Labs' investor relations website.

What products does Establishment Labs offer?

Establishment Labs offers silicone gel-filled breast implants branded as Motiva Implants® and the Divina® 3D Simulation System.